Gilead Sciences, Inc. (0QYQ.IL)

65.20 -0.18 (-0.28%) As of 04:01PM BST. Market open.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 17,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel P. O'Day	Chairman & CEO	7.27M	N/A	1964
Mr. Andrew D. Dickinson	Exec. VP & CFO	2.94M	N/A	1970
Ms. Deborah H. Telman	Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.	2.32M	N/A	1965
Ms. Johanna Mercier	Chief Commercial Officer	3.32M	N/A	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	3.07M	N/A	1963
Ms. Sandra Patterson	Sr. VP, Corp. Controller & Principal Accounting Officer	N/A	N/A	1967
Ms. Jacquie Ross C.F.A.	VP of Investor Relations	N/A	N/A	N/A
Ms. Jyoti K. Mehra	Exec. VP of HR	N/A	N/A	1976
Dr. Linda Slanec Higgins Ph.D.	Sr. VP of Research, Innovation & Portfolio	N/A	N/A	1962
Dr. Rudolf Ertl	Sr. VP of Commercial Operations of Australia, Canada, Europe	N/A	N/A	1946

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 1 October 2023 is 1. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.